28 327

Cited 13 times in

Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.

An, YS; Sheen, SS; Oh, YJ; Hwang, SC; Yoon, JK
Annals of nuclear medicine, 21(10):585-592, 2007
Journal Title
Annals of nuclear medicine
OBJECTIVE: This study was performed to evaluate the effects of intravenous (i.v.) contrast agent on semi-quantitative values and lymph node (LN) staging of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with lung cancer.

METHODS: Thirty-five patients with lung cancer were prospectively included. Whole-body PET and nonenhanced CT images were acquired 60 min following the i.v. injection of 370 MBq 18F-FDG and subsequently, enhanced-CT images were acquired with the i.v. administration of 400 mg iodinated contrast agent without positional change. PET images were reconstructed with both nonenhanced and enhanced CTs, and the maximum and average standardized uptake values (SUVmax and SUVave) calculated from lung masses, LNs, metastatic lesions, and normal structures were compared. To evaluate the effects of the i.v. contrast agent on LN staging, we compared the LN status on the basis of SUVs (cut-offs; SUVmax=3.5, SUVave=3.0).

RESULTS: The mean differences of SUVmax in normal structures between enhanced and nonenhanced PET/CT were 15.23%+/-13.19% for contralateral lung, 8.53%+/-6.11% for aorta, 5.85%+/-4.99% for liver, 5.47%+/-6.81% for muscle, and 2.81%+/-3.05% for bone marrow, and those of SUVave were 10.17%+/-9.00%, 10.51%+/-7.89%, 4.95%+/-3.89%, 5.66%+/-9.12%, and 2.49%+/-2.50%, respectively. The mean differences of SUVmax between enhanced and nonenhanced PET/CT were 5.89%+/-3.92% for lung lesions (n=41), 6.27%+/-3.79% for LNs (n=76), and 3.55%+/-3.38% for metastatic lesions (n=35), and those of SUVave were 3.22%+/-3.01%, 2.86%+/-1.71%, and 2.33%+/-3.95%, respectively. Although one LN status changed from benign to malignant because of contrast-related artifact, there was no up- or down-staging in any of the patients after contrast enhancement.

CONCLUSIONS: An i.v. contrast agent may be used in PET/CT without producing any clinically significant artifact.
MeSH terms
AdultAgedAged, 80 and overArtifacts*Contrast Media/administration & dosageFemaleFluorodeoxyglucose F18/diagnostic use*HumansIopamidol/administration & dosageIopamidol/analogs & derivatives*Iopamidol/diagnostic useLung/drug effectsLung/radiographyLung/radionuclide imagingLung Neoplasms/diagnosis*MaleMiddle AgedPositron-Emission Tomography/methods*Radiopharmaceuticals/diagnostic useSubtraction TechniqueTomography, X-Ray Computed/methods*
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Nuclear Medicine & Molecular Imaging
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
AJOU Authors
안, 영실신, 승수오, 윤정황, 성철윤, 준기
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.